These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28715811)

  • 21. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results.
    Lafuente M; Ortín L; Argente M; Guindo JL; López-Bernal MD; López-Román FJ; García MJ; Domingo JC; Lajara J
    Retina; 2017 Jul; 37(7):1277-1286. PubMed ID: 27787443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
    Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
    Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: A 4-Year Study.
    Epstein D; Amrén U
    Retina; 2018 Jan; 38(1):183-186. PubMed ID: 28323678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters.
    Takasago Y; Fujita T; Nakano Y; Osaka R; Miyake M; Muraoka Y; Tsujikawa A
    Acta Ophthalmol; 2019 Dec; 97(8):e1048-e1053. PubMed ID: 31127694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema.
    Chen YY; Chen PY; Chen FT; Chen YJ; Wang JK
    Int Ophthalmol; 2018 Feb; 38(1):293-299. PubMed ID: 28176171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
    Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
    Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.
    Patrao NV; Antao S; Egan C; Omar A; Hamilton R; Hykin PG; Sivaprasad S; Rajendram R;
    Am J Ophthalmol; 2016 Dec; 172():51-57. PubMed ID: 27637784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
    Hrarat L; Fajnkuchen F; Boubaya M; Lévy V; Sarda V; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    Ophthalmologica; 2016; 236(4):207-214. PubMed ID: 27898414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab.
    Talks SJ; Bhatia D; Menon G; Cole A; Eleftheriadis H; Downey L; Chong NV; Sivaprasad S;
    Eye (Lond); 2019 Jun; 33(6):930-937. PubMed ID: 30728488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
    Stefanickova J; Cunha-Vaz J; Ulbig M; Pearce I; Fernández-Vega Sanz A; Theodossiadis P; Kodjikian L; Izmailov A; Muston D; Vassilev Z; Lamotte B; Tückmantel C; Friedl S; Altemark A; Schwarz HJ; Katz T;
    Acta Ophthalmol; 2018 Dec; 96(8):e942-e949. PubMed ID: 29696809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
    Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial.
    Eichenbaum DA; Duerr E; Patel HR; Pollack SM
    Ophthalmic Surg Lasers Imaging Retina; 2018 Nov; 49(11):e191-e197. PubMed ID: 30457655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study).
    Heng LZ; Sivaprasad S; Crosby-Nwaobi R; Saihan Z; Karampelas M; Bunce C; Peto T; Hykin PG
    Br J Ophthalmol; 2016 Jun; 100(6):802-7. PubMed ID: 26472406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema.
    Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM
    Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.